دورية أكاديمية
Association of mucus eosinophil-derived neurotoxin levels with disease control status in patients with chronic rhinosinusitis.
| العنوان: | Association of mucus eosinophil-derived neurotoxin levels with disease control status in patients with chronic rhinosinusitis. |
|---|---|
| المؤلفون: | Huang X; Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China., Liu Z; Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China., Bleier BS; The Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA, USA., Song Y; Department of Otolaryngology Head and Neck Surgery, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing, 100191, People's Republic of China.; Department of Otorhinolaryngology Head and Neck Surgery, Yanan City Hospital of Peking, University 3, Hospital, Yanan City, People's Republic of China., Wu D; Department of Otolaryngology Head and Neck Surgery, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing, 100191, People's Republic of China. davidwuorl@163.com. |
| المصدر: | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2024 Aug; Vol. 281 (8), pp. 4191-4199. Date of Electronic Publication: 2024 May 03. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Country of Publication: Germany NLM ID: 9002937 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1434-4726 (Electronic) Linking ISSN: 09374477 NLM ISO Abbreviation: Eur Arch Otorhinolaryngol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Heidelberg : Springer International, c1990- |
| مواضيع طبية MeSH: | Sinusitis*/complications , Sinusitis*/metabolism , Rhinitis*/metabolism , Rhinitis*/complications , Mucus*/metabolism , Eosinophil-Derived Neurotoxin*/metabolism , Biomarkers*/metabolism, Humans ; Male ; Female ; Chronic Disease ; Middle Aged ; Adult ; Prospective Studies ; Case-Control Studies ; Severity of Illness Index ; Nasal Mucosa/metabolism ; Sino-Nasal Outcome Test ; Aged ; Rhinosinusitis |
| مستخلص: | Objective: Identifying the biomarkers for uncontrolled chronic rhinosinusitis (CRS) is important for directing treatment decisions. Eosinophilia has been reported to be involved in the poor disease control of CRS and mucus eosinophil-derived neurotoxin (EDN) is potentially a biomarker of intense eosinophil activation. This study aimed to assess the relationship between mucus EDN levels, disease severity, and degree of CRS control. Methods: A total of 150 adult patients with CRS and 25 healthy controls were prospectively enrolled. The nasal mucus and tissue specimens were collected to analyze EDN levels. Disease severity was assessed by Lund-Mackay score and 22-item Sino-Nasal Outcome Test (SNOT-22) score. Five CRS symptom severities during the prior month (nasal blockage, rhinorrhoea/postnasal drip, facial pain/pressure, smell, sleep disturbance or fatigue), use of rescue medications in the last six months, and the presence of diseased mucosa on nasal endoscopy were obtained. Consistent with the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 CRS control criteria, uncontrolled CRS was defined as meeting at least three items. Results: 40% of patients with CRS presented with uncontrolled status. Patients with uncontrolled CRS had significantly higher nasal mucus EDN levels (P = 0.010), percentage of blood eosinophil (P = 0.015), SNOT-22 score (P < 0.001), Lund-Mackay score (P = 0.008), and a more eosinophilic dominant phenotype of CRS (P < 0.001) than patients with controlled CRS. Furthermore, mucus EDN levels were positively correlated with blood eosinophils (r = 0.541, P = 0.005), SNOT-22 score (r = 0.460, P = 0.021), and Lund-Mackay score (r = 0.387, P = 0.039). Mucus EDN levels were the significant parameter related to uncontrolled CRS in multivariable analysis after adjusting for patient demographics and comorbidities (odds ratio = 1.323; P = 0.004). Conclusions: Mucus EDN levels may be a potential biomarker for identifying the CRS control status. (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe—an underestimated disease. A GA 2 LEN study. Allergy. 2011;66(9):1216–23. Hirsch AG, Stewart WF, Sundaresan AS, Young AJ, Kennedy TL, Scott Greene J et al (2017) Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy 72(2):274–281. (PMID: 10.1111/all.1304227590749) Shi JB, Fu QL, Zhang H, Cheng L, Wang YJ, Zhu DD et al (2015) Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy 70(5):533–539. (PMID: 10.1111/all.1257725631304) Baguley C, Brownlow A, Yeung K, Pratt E, Sacks R, Harvey R (2014) The fate of chronic rhinosinusitis sufferers after maximal medical therapy. Int Forum Allergy Rhinol 4(7):525–532. (PMID: 10.1002/alr.2131524610673) Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1–464. Alanin MC, Hopkins C (2020) Effect of functional endoscopic sinus surgery on outcomes in chronic rhinosinusitis. Curr Allergy Asthma Rep 20(7):27. (PMID: 10.1007/s11882-020-00932-632462321) van der Veen J, Seys SF, Timmermans M, Levie P, Jorissen M, Fokkens WJ et al (2017) Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy 72(2):282–290. (PMID: 10.1111/all.1298327392210) Sedaghat AR, Phillips KM. Chronic rhinosinusitis disease control: a review of the history and the evidence. Expert Rev Clin Immunol. 2023:1–8. Zhou J, Yuan F, Huang T, Zhu L, Wu D (2023) Current understanding of disease control and its application in patients with chronic rhinosinusitis. Front Cell Infect Microbiol 13:1104444. (PMID: 10.3389/fcimb.2023.110444437342244) Tao X, Chen F, Sun Y, Wu S, Hong H, Shi J et al (2018) Prediction models for postoperative uncontrolled chronic rhinosinusitis in daily practice. Laryngoscope 128(12):2673–2680. (PMID: 10.1002/lary.2726730295929) Wang K, Deng J, Yang M, Chen Y, Chen F, Gao WX et al (2019) Concordant systemic and local eosinophilia relates to poorer disease control in patients with nasal polyps. World Allergy Organ J 12(8):100052. (PMID: 10.1016/j.waojou.2019.10005231452832) Penttilä E, Sillanpää S, Vento SI, Myller J, Koskinen A, Hammarén-Malmi S, et al. Eosinophilia, asthma, NERD and the use of oral corticosteroids predict uncontrolled chronic rhinosinusitis with nasal polyps after surgery. Asian Pac J Allergy Immunol. 2021. Epub 2021/09/21. doi: https://doi.org/10.12932/ap-310321-1102 . Jiang L, Wang K, Lin T, Jiang Y, Gao W, Li C et al (2022) A novel risk score for disease control prediction of chronic rhinosinusitis. Clin Otolaryngol 47(5):568–576. (PMID: 10.1111/coa.13949356224599542583) Delemarre T, Bochner BS, Simon HU, Bachert C (2021) Rethinking neutrophils and eosinophils in chronic rhinosinusitis. J Allergy Clin Immunol 148(2):327–335. (PMID: 10.1016/j.jaci.2021.03.024338950028355033) Gevaert P, Han JK, Smith SG, Sousa AR, Howarth PH, Yancey SW et al (2022) The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 12(11):1413–1423. (PMID: 10.1002/alr.22994352438039790271) Lou H, Zhang N, Bachert C, Zhang L (2018) Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement. Int Forum Allergy Rhinol 8(11):1218–1225. (PMID: 10.1002/alr.2221430296011) Kwah JH, Somani SN, Stevens WW, Kern RC, Smith SS, Welch KC et al (2020) Clinical factors associated with acute exacerbations of chronic rhinosinusitis. J Allergy Clin Immunol 145(6):1598–1605. (PMID: 10.1016/j.jaci.2020.01.023320045238177481) Gon Y, Ito R, Hattori T, Hiranuma H, Kumasawa F, Kozu Y et al (2015) Serum eosinophil-derived neurotoxin: correlation with persistent airflow limitation in adults with house-dust mite allergic asthma. Allergy Asthma Proc 36(6):e113–e120. (PMID: 10.2500/aap.2015.36.388426534742) Lee Y, Lee JH, Yang EM, Kwon E, Jung CG, Kim SC et al (2019) Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics. Allergy Asthma Immunol Res 11(3):394–405. (PMID: 10.4168/aair.2019.11.3.394309123286439192) An J, Lee JH, Sim JH, Song WJ, Kwon HS, Cho YS et al (2020) Serum eosinophil-derived neurotoxin better reflect asthma control status than blood Eosinophil counts. J Allergy Clin Immunol Pract 8(8):2681–8.e1. (PMID: 10.1016/j.jaip.2020.03.03532304842) Malinovschi A, Rydell N, Fujisawa T, Borres MP, Kim CK (2023) Clinical potential of eosinophil-derived neurotoxin in asthma management. J Allergy Clin Immunol Pract 11(3):750–761. (PMID: 10.1016/j.jaip.2022.11.04636581068) Konikoff MR, Blanchard C, Kirby C, Buckmeier BK, Cohen MB, Heubi JE et al (2006) Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin Gastroenterol Hepatol 4(11):1328–1336. (PMID: 10.1016/j.cgh.2006.08.01317059896) Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR et al (2008) Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 205(1):79–90. (PMID: 10.1084/jem.2006202718195069) Kim HS, Yang HJ, Song DJ, Lee YJ, Suh DI, Shim JY et al (2022) Eosinophil-derived neurotoxin: an asthma exacerbation biomarker in children. Allergy Asthma Proc 43(2):133–139. (PMID: 10.2500/aap.2022.43.21000135317890) Tsuda T, Maeda Y, Nishide M, Koyama S, Hayama Y, Nojima S et al (2019) Eosinophil-derived neurotoxin enhances airway remodeling in eosinophilic chronic rhinosinusitis and correlates with disease severity. Int Immunol 31(1):33–40. (PMID: 10.1093/intimm/dxy06130239772) Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU et al (2021) International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 11(3):213–739. (PMID: 10.1002/alr.2274133236525) Wu D, Hong J, Chang F, Wei Y (2022) Development of a novel centrifugal extraction device to collect the olfactory cleft mucus. Acta Otolaryngol 142(3–4):323–328. (PMID: 10.1080/00016489.2022.204722335289706) Wu D, Liu Z, Bleier BS, Huang X, Hong J. Olfactory cleft mucus eosinophil-derived neurotoxin better reflects olfactory loss than blood eosinophil counts in patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2023. Epub 2023/06/02. https://doi.org/10.1002/alr.23202 . Wu D, Li Y, Bleier BS, Wei Y (2020) Superior turbinate eosinophilia predicts olfactory decline in patients with chronic rhinosinusitis. Ann Allergy Asthma Immunol 125(3):304–10.e1. (PMID: 10.1016/j.anai.2020.04.02732387168) DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845. (PMID: 10.2307/25315953203132) Sedaghat AR, Fokkens WJ, Lund VJ, Hellings PW, Kern RC, Reitsma S, et al. Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study. Rhinology. 2023. Epub 2023/10/07. https://doi.org/10.4193/Rhin23.335 . Sedaghat AR, Phillips KM (2023) Chronic rhinosinusitis disease control: a review of the history and the evidence. Expert Rev Clin Immunol 19(8):903–910. (PMID: 10.1080/1744666X.2023.222902737343511) Ali A, Fakunle DR, Yu V, McDermott S, Previtera MJ, Meier JC et al (2023) Heterogeneity in the definition of chronic rhinosinusitis disease control: a systematic review of the scientific literature. Eur Arch Otorhinolaryngol 280(12):5345–5352. (PMID: 10.1007/s00405-023-08090-x37378726) Sedaghat AR, Phillips KM (2023) Defining “control” of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 31(1):17–23. (PMID: 10.1097/MOO.000000000000085836730615) Racette SD, Wijewickrama RC, Jayaprakash V, Sherris DA, Santos C, Kita H et al (2017) Correlation of symptoms, clinical signs, and biomarkers of inflammation in postsurgical chronic rhinosinusitis. Ann Otol Rhinol Laryngol 126(6):455–462. (PMID: 10.1177/000348941770193928376637) Yang D, Rosenberg HF, Chen Q, Dyer KD, Kurosaka K, Oppenheim JJ (2003) Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 102(9):3396–3403. (PMID: 10.1182/blood-2003-01-015112855582) Han Z, Junxu, Zhong N. Expression of matrix metalloproteinases MMP-9 within the airways in asthma. Respir Med. 2003;97(5):563–7. Yeo NK, Eom DW, Oh MY, Lim HW, Song YJ (2013) Expression of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 1 in nonrecurrent vs recurrent nasal polyps. Ann Allergy Asthma Immunol 111(3):205–210. (PMID: 10.1016/j.anai.2013.06.02323987197) Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92(8):827–839. (PMID: 10.1161/01.RES.0000070112.80711.3D12730128) Viskens AS, Wils T, Van Bulck P, Cools L, Vanderveken O, Hellings PW (2022) Multiple reasons underlaying uncontrolled disease in the majority of chronic rhinosinusitis patients. Front Allergy 3:1048385. (PMID: 10.3389/falgy.2022.104838536583193) Wautlet A, Bachert C, Desrosiers M, Hellings PW, Peters AT (2023) The management of chronic rhinosinusitis with nasal polyps (CRSwNP) With biologics. J Allergy Clin Immunol Pract 11(9):2642–2651. (PMID: 10.1016/j.jaip.2023.04.05437182568) |
| معلومات مُعتمدة: | BYSYZD2023029 Key clinical projects of Peking University Third Hospital; 82000954 Natural Science Foundation of China; Z201100006820086 Beijing Science and Technology Nova Program; QML20190617 Beijing Hospitals Authority Youth Program; XMLX202136 Beijing Hospitals Authority Clinical Medicine Development of Special Funding; 2021JQ-942 Shan xi Natural Science Foundation |
| فهرسة مساهمة: | Keywords: Biomarkers; Chronic rhinosinusitis; Disease control; Eosinophil-derived neurotoxin; Nasal mucus; Predictor |
| المشرفين على المادة: | EC 3.1.- (Eosinophil-Derived Neurotoxin) 0 (Biomarkers) |
| تواريخ الأحداث: | Date Created: 20240503 Date Completed: 20240723 Latest Revision: 20240723 |
| رمز التحديث: | 20240723 |
| DOI: | 10.1007/s00405-024-08695-w |
| PMID: | 38700538 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1434-4726 |
|---|---|
| DOI: | 10.1007/s00405-024-08695-w |